NCT06863922View on ClinicalTrials.gov

A Pilot Study of Berberine (Soloways ™) in Patients with Type 2 Diabetes Mellitus Carrying TCF7L2 Polymorphisms

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 3, 2024

Primary Completion Date

August 14, 2024

Study Completion Date

October 22, 2024

Conditions
Diabetes Mellitus
Interventions
DIETARY_SUPPLEMENT

Berberine

Berberine 500-1000 mg, administered 2-3 times per day for 12 weeks, in addition to standard of care

DIETARY_SUPPLEMENT

Berberine

Berberine 500-1000 mg, administered 2-3 times per day for 12 weeks, in addition to standard of care

Trial Locations (1)

630090

Center for New Medical Technologies, Novosibirsk

All Listed Sponsors
collaborator

Center for New Medical Technologies, Novosibirsk, Russia

OTHER

lead

S.LAB (SOLOWAYS)

OTHER

NCT06863922 - A Pilot Study of Berberine (Soloways ™) in Patients with Type 2 Diabetes Mellitus Carrying TCF7L2 Polymorphisms | Biotech Hunter | Biotech Hunter